Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

被引：2

作者：

Pfeifer, Heike ^{[1
]}

Wystub, Sylvia ^{[2
]}

Binckebanck, A. ^{[1
]}

Wassmann, Barbara

Kaebisch, Andreas

Luebbert, Michael ^{[3
]}

Leimer, Lothar ^{[4
]}

Giagounidis, Aristoteles ^{[5
]}

Gassmann, Winfried ^{[6
]}

Brueck, Patrick ^{[2
]}

Serve, Hubert ^{[1
]}

Hoelzer, Dieter ^{[7
]}

Ottmann, Oliver G. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Dept Med, D-60054 Frankfurt, Germany

[2] Goethe Univ Frankfurt, Dept Hematol, D-60054 Frankfurt, Germany

[3] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany

[4] Robert Bosch Krankenhaus, Stuttgart, Germany

[5] St Johannes Hosp, Med Klin 2, Duisburg, Germany

[6] St Marien Krankenhaus gGmbH, Siegen, Germany

[7] Goethe Univ Hosp, Dept Internal Med Hematol & Oncol 2, Frankfurt, Germany

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1503.1503

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1503

引用

页数：2

共 50 条

[31] Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Lim, Sung-Nam
Lee, Kyoo-Hyung
Kim, Dae-Young
Lee, Je-Hwan
Lee, Jung-Hee
Chi, Hyun-Sook
Joo, Young-Don
Lee, Won Sik
Lee, Sang Min
Park, Seonyang
Kim, Inho
Sohn, Sang Kyun
Moon, Joon Ho
Ryoo, Hun-Mo
Bae, Sung Hwa
Kim, Min Kyoung
Yang, Deok-Hwan
Eom, Hyeon-Seok
Lee, Gyeong-Won
Jung, Chul Won
Won, Jong-Ho
Kim, Hawk
Lee, Jae-Hoon
Shin, Ho-Jin
Kim, Ho Young
Hyun, Myung Soo
Kim, Hyeoung Joon
BLOOD, 2014, 124 (21)
[32] Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study
Guan, Fangshu
Yang, Luxin
Chen, Yi
Shi, Jimin
Song, Xiaolu
Lai, Xiaoyu
Lu, Ying
Liu, Lizhen
Ouyang, Guifang
Zhao, Yanmin
Yu, Jian
Xu, Yang
Lan, Jianping
Fu, Huarui
Zhao, Yi
Qiu, Xi
Zhu, Panpan
Cai, Zhen
Huang, He
Luo, Yi
CANCER, 2024, 130 (12) : 2139 - 2149
[33] Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Pfeifer, Heike
Wassmann, B.
Bethge, Wolfgang A.
Dengler, Jolanta
Bornhaeuser, Martin
Stadler, Michael
Beelen, Dietrich
Guenther, Andreas
Vucinic, Vladan
Burmeister, Thomas
Stelljes, Matthias
Schwerdtfeger, Rainer
Schaefer-Eckhart, Kerstin
Bader, Peter
Kreyenberg, Hermann
Schuld, Peter
Serve, Hubert
Hoelzer, Dieter
Goekbuget, Nicola
Ottmann, Oliver G.
BLOOD, 2011, 118 (21) : 112 - 113
[34] Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Lee, Hun Ju
Kantarjian, Hagop M.
Thomas, Deborah A.
Faderl, Stefan
Koller, Charles
Ferrajoli, Alessandra
Jabbour, Elias
Garris, Rebecca
Kebriaei, Partow
Champlin, Richard
Borthakur, Gautam
Wierda, William G.
Burger, Jan A.
Cortes, Jorge E.
O'Brien, Susan
Ravandi, Farhad
BLOOD, 2011, 118 (21) : 655 - 656
[35] Long-Term Outcome of Relapsed Adult Philadelphia Chromosome-Positve Acute Lymphoblastic Leukemia Treated with Continuous Imatinib Plus Combination Therapy
Lim, Sung Nam
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S1 - S1
[36] Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation
Kuang, Pu
Liu, Ting
Pan, Ling
Zhu, Huanling
Wu, Yu
Ye, Yuanxin
Xiang, Bing
Ma, Hongbing
Chang, Hong
Niu, Ting
Cui, Xu
He, Chuan
Li, Jianjun
Ji, Jie
Huang, Jie
Dong, Tian
Dai, Yang
Lu, Xiaojun
Qing, Shenglan
Wu, Huaxin
Liang, Xiaogong
Wang, Xiaoyu
Wu, Chunnong
LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2321 - 2329
[37] IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial
Ito, Yoshikiyo
Ozawa, Hidetoshi
Eto, Tetsuya
Miyamoto, Toshihiro
Kamimura, Tomohiko
Ogawa, Ryosuke
Uchida, Naoyuki
Wake, Atsusi
Fujisaki, Tomoaki
Ohno, Yuju
Takase, Ken
Okumura, Hirokazu
Takamatsu, Yasushi
Kawano, Noriaki
Akashi, Koichi
Nagafuji, Koji
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (01) : 103 - 112
[38] The overexpression of spliced oncogenic Ikaros isoforms in Philadelphia-positive (Ph plus) acute lymphoblastic leukemia (ALL) patients is a new mechanism of resistance to tyrosine kinase inhibitors.
Iacobucci, I.
Lonelti, A.
Ottaviani, E.
Cilloni, D.
Messa, F.
Paolini, S.
Papayannidis, C.
Panagiota, G.
Soverini, S.
Amabile, M.
Poerio, A.
Rondoni, M.
Saglio, G.
Pane, F.
Berton, G.
Baruzzi, A.
Vitale, A.
Foa, R.
Baccarani, M.
Martinelli, Giovanni
BLOOD, 2007, 110 (11) : 221A - 222A
[39] Characteristics of ponatinib (PON) therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) patients (pts) in real-world (RW) clinical practice compared to the PACE trial.
Mauro, Michael J.
McGarry, Lisa
Yang, Mo
Lustgarten, Stephanie
Huang, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Geraldo Rocha, Vanderson
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 398868 - 398868

← 1 2 3 4 5 →